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Abstract 
Background: Large population-based translational epigenetic studies are emerging due to recent technological 
advances that have made molecular analyses possible. For example, the Infinium HumanMethylation450 Beadchip 
(HM450K) has enabled studies of genome-wide methylation on a scale not previously possible. However, application 
of the HM450K to DNA extracted from formalin-fixed paraffin-embedded (FFPE) tumour material has been more chal-
lenging than application to high quality DNA extracted from blood. To facilitate the application of this assay consist-
ently across a large number of FFPE tumour-enriched DNA samples we have devised a modification to the HM450K 
protocol for FFPE that includes an additional quality control (QC) checkpoint.
Results: QC checkpoint 3 was designed to assess the presence of DNA after bisulfite conversion and restoration, 
just prior to application of the HM450K assay. DNA was extracted from 474 archival FFPE breast tumour material. Five 
samples did not have a detectable amount of DNA with an additional 42 failing to progress past QC checkpoint 3. 
Genome-wide methylation was measured for the remaining 428 tumour-enriched DNA. Of these, only 4 samples 
failed our stringent HM450K data criteria thus representing a 99 % success rate. Using prior knowledge about meth-
ylation marks associated with breast cancer we further explored the quality of the data. Twenty probes in the BRCA1 
promoter region showed increased methylation in triple-negative breast cancers compared to Luminal A, Luminal B 
and HER2-positive breast cancer subtypes. Validation of this observation in published data from The Cancer Genome 
Atlas (TCGA) Network (obtained from DNA extracted from fresh frozen tumour samples) confirms the quality of the 
data obtained from the improved protocol.
Conclusions: The modified protocol is suitable for the analysis of FFPE tumour-enriched DNA and can be system-
atically applied to hundreds of samples. This protocol will have utility in population-based translational epigenetic 
studies and is applicable to a wide variety of translated studies interested in analysis of methylation and its role in the 
predisposition to disease and disease progression.
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Background
Recent technological advances have made genome-
wide studies of epigenetics possible on a scale suitable 
for large population-based studies (akin to what SNP 
chips enabled for genome-wide association studies). For 
example, the Infinium HumanMethylation450 Bead-
chip (HM450K) has enabled studies of genome-wide 
methylation on a scale not previously possible. However, 
application of the HM450K to DNA extracted from for-
malin-fixed paraffin-embedded (FFPE) tumour material 
has been more challenging than application to high qual-
ity DNA extracted from blood.
Archival FFPE tumour material represents a precious 
resource for many large epidemiological studies. How-
ever, the use of this material is often challenging as DNA 
extracted from FFPE tumour material is frequently of low 
quantity and highly degraded [1], thus making it difficult 
to obtain consistent molecular analysis across a large 
number of samples.
Genome-wide detection methodologies based on next-
generation sequencing and microarrays applied to FFPE 
tumour-enriched DNA have the potential to address 
many of the current significant research questions being 
pursued in translational epigenetic studies. However, 
most of these platforms require large amounts of high 
quality DNA. Alternate protocols are therefore needed 
to address the issues of DNA quantity and quality asso-
ciated with DNA extracted from FFPE tumour material 
so that the potential of combining these platforms and 
resources can be realised for translational studies.
We have previously shown that DNA extracted from 
dried blood spots can be successfully applied to the 
HM450K platform. High quality and reproducible results 
were obtained from DNA extracted from matched archi-
val dried blood spot and frozen buffy coat (correlation 
coefficient r  >  0.99) [2]. Although more recent stud-
ies have demonstrated the reliable application of the 
HM450K platform to FFPE tumour-enriched DNA com-
pared with DNA extracted from fresh frozen material 
[3, 4], they do not address the issues faced by research-
ers wanting to apply this assay to large population stud-
ies. Moran and colleagues measured methylation on 
the HM450K platform in DNA extracted from matched 
fresh frozen tumour and newly fixed FFPE tumour mate-
rial. This work addressed the effect of formalin but it did 
not consider the possible effect that long term storage of 
FFPE tumour material might have on DNA quality and 
assay output [3]. This issue was considered by Dumenil 
and colleagues who compared DNA extracted from fresh 
frozen material with FFPE tumour-enriched DNA that 
was stored between 4 and 19  years (storage conditions 
unspecified). Based on the signal of the 3000 most dif-
ferential probes between the two DNA types, they found 
that the difference in methylation signals between FFPE 
tumour-enriched DNA and DNA extracted from fresh 
frozen material correlated with the length of storage time 
[4].
In both studies, FFPE tumour-enriched DNA was 
restored with the recommended Infinium HD FFPE 
Restore protocol (Illumina, San Diego, CA, USA) that 
has been shown to improve the performance of FFPE 
tumour-enriched DNA on the HM450K [5, 6]. Highly 
correlated methylation values were observed between 
DNA extracted from matched fresh frozen and restored 
FFPE tumour-enriched DNA compared with unrestored 
FFPE tumour-enriched DNA (r > 0.91 vs r > 0.81). Addi-
tionally, highly reproducible data were obtained from 
restored FFPE tumour-enriched DNA (r  =  0.99) com-
pared with their unrestored counterparts (r =  0.90) [5]. 
The same observations were reported when Siegel and 
colleagues compared the restoration protocol to an alter-
nate ligation method (using the REPLI-g ligase) in DNA 
extracted from FFPE tumour material and matched fresh 
frozen material [6].
All four studies described above used relatively moder-
ate quantities of DNA (100–500 ng) as starting material 
for bisulfite conversion, followed by the Infinium resto-
ration and HM450K protocols [3–6]. However, obtaining 
this amount of DNA is challenging to achieve consistently 
across a large number of archival FFPE tumour samples. 
Further, these reports did not measure the presence of 
FFPE tumour-enriched DNA after bisulfite conversion 
and restoration, making the subsequent performance of 
these samples on the HM450K platform unpredictable.
To address these issues, we adopted a modified proto-
col (Fig. 1) based on the recommended Illumina Infinium 
workflow for FFPE tumour-enriched DNA which incor-
porated a third quality control (QC) checkpoint in the 
form of an in-house designed bisulfite-specific qPCR 
assay to assess the capacity of the protocol to support 
large population-based translation epigenetics studies.
Methods
Melbourne Collaborative Cohort Study
The study was performed on material from 474 breast 
cancer affected female participants of the Melbourne 
Collaborative Cohort Study (MCCS). The MCCS is a 
prospective study of more than 40,000 men and women 
aged 40–69 years at baseline who were recruited between 
the years 1990–1994 [7]. Pathology material related to 
each breast cancer case had previously been retrieved 
from the diagnostic service laboratory and reviewed by 
qualified pathologists. Representative haematoxylin and 
eosin (H&E) stained sections and unstained sections 
(3 μm) had been prepared and stored desiccated at 4 °C 
for up to 15  years. Immunohistochemical staining and 
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breast cancer subtyping were conducted as described by 
Blows et al. [8]. Written informed consent was obtained 
from each participant and the study was approved by the 
Human Research Ethics Committee of Cancer Council 
Victoria [7].
DNA extraction from FFPE breast tumour material
The tumour area most suitable for macrodissection was 
identified by a qualified pathologist (CAM) and recorded 
by directly marking up the representative H&E stained 
section. Macrodissection of FFPE breast tumour mate-
rial was performed on an average of two 3 μm unstained 
sections (corresponding to the marked H&E stained sec-
tion). DNA was extracted using the QIAamp DNA FFPE 
protocol (Qiagen, Hilden, Germany) as per the manufac-
turer’s instructions except that the tumour material was 
incubated in Buffer ATL at 56 °C for 48 h, with 20 ul of 
Proteinase K (20  mg/ml) replenished at 0 and 24  h to 
increase the digestion of proteins. FFPE tumour-enriched 
DNA was eluted twice in Buffer ATE to achieve a final 
elution volume of 20 μl.
QC checkpoint 1: Qubit® dsDNA BR assay
The presence of FFPE tumour-enriched DNA was meas-
ured using the Qubit® dsDNA BR Assay kit on the 
Qubit® Fluorometer (Life Technologies, Carlsbad, CA, 
USA) as per manufacturer’s instructions. Samples with 
undetectable DNA amounts were not further progressed 
through the workflow.
QC checkpoint 2: Infinium HD FFPE QC assay
The quality of FFPE tumour-enriched DNA was assessed 
using the Infinium HD QC assay (Illumina, San Diego, 
CA, USA) on the LightCycler® 480 System (Roche, Basel, 
Switzerland) with subsequent data analysis performed 
as per the manufacturers’ instructions and as described 
previously [3, 4]. Taking into consideration the poor 
quality of our samples, the recommended ∆Cq threshold 
was relaxed so that samples that had ∆Cq values of ≤6 
(instead of the recommended 5) were further processed 
[3, 4].
Sodium bisulfite conversion
FFPE tumour-enriched DNA samples (16–750  ng) were 
bisulfite converted using the EZ DNA Methylation-Gold 
kit (Zymo, Irvine, CA, USA), and eluted in a final volume 
of 8 μl elution buffer.
Restoration of bisulfite converted FFPE tumour‑enriched 
DNA
Restoration of bisulfite converted FFPE tumour-enriched 
DNA was performed using the Infinium HD FFPE 
Restore kit (Illumina, San Diego, CA, USA) as per the 
manufacturer’s instructions and as previously described 
[3, 4] except that restored bisulfite converted samples 
were eluted in a final volume of 10 ul nuclease free water.
QC checkpoint 3: bisulfite‑specific qPCR assay
The presence of FFPE tumour-enriched DNA after 
bisulfite conversion and restoration was determined using 
an in-house qPCR assay. Primers specific for bisulfite 
converted DNA were designed using EpiDesigner (http://
www.epidesigner.com) (forward sequence: 5′ tAA GGT 
AtA ATt AGA GGA TGG GAG GGA t; reverse sequence: 
5′ aaC AAA CTC Aaa TAa AAT TCT TCC TC) to 
amplify a 134 bp region (hg19:chr17:41277493-41277626) 
within the promoter of the breast cancer 1, early onset 
(BRCA1) gene (GenBank: L78833.1) [9]. Lower-case let-
ters correspond to converted cytosines. The amplicon 
sequence is as follows: 5′ tAA GGT AtA ATt AGA GGA 
TGG GAG GGA tAG AAA GAG CCA AGC GTC TCT 
Fig. 1 Workflow diagram for assessing the suitability of FFPE tumour-
enriched DNA on the HM450K platform. A novel checkpoint (QC 
checkpoint 3) has been incorporated in addition to the standard 
protocol to assess DNA availability after sodium bisulfite modification 
and restoration. The number of samples entering and exiting each 
QC checkpoint is as indicated
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CGG GGC TCT GGA TTG GCC ACC CAG TCT GCC 
CCC GGA TGA CGT AAA AGG AAA GAG ACG GAA 
GAG GAA GAA TTt TAt tTG AGT TTG tt. CpG dinu-
cleotides are in bold. The qPCR primers and the PCR 
conditions were developed to ensure that products be 
unaffected by the methylation status of the template (data 
not shown) [10].
Each reaction consisted of 1X SYBR Green I Master 
(Roche, Basel, Switzerland), 300 pM each of forward and 
reverse primers (Integrated DNA technologies, Coral-
ville, IA), and 3 ul diluted restored bisulfite converted 
FFPE tumour-enriched DNA (diluted 1:3 in nuclease free 
water). The reaction was equilibrated to 10 μl with nucle-
ase free water (Life Technologies, Carlsbad, CA, USA).
QPCR cycling conditions were as follows: initial poly-
merase activation for 5 min at 95 °C followed by 40 cycles 
of DNA denaturation for 10 s at 95 °C, primer annealing 
for 30 s at 60 °C and extension for 90 s at 72 °C. Subse-
quent melting of the amplified product was performed 
from 97  °C to 65  °C for 60  s. Fluorescent data was 
acquired on the green channel.
All samples were assayed in duplicate and non–bisulfite 
converted, unrestored U266 multiple myeloma cell line 
DNA was used as a negative control. Subsequent data 
analysis was performed similar to QC checkpoint 2 
except that the difference in Cq value (∆Cq) was deter-
mined by subtracting the average Cq value of each FFPE 
tumour-enriched DNA sample from the average Cq 
value of the negative control (∆Cq= Average CqNegative 
control − Average CqTumour-enriched DNA). Using the Infinium-
recommended ∆Cq threshold for QC checkpoint 2 as 
a reference (Cq difference of 5) and taking into account 
the poor quality and limited quantity of FFPE tumour-
enriched DNA, a more relaxed ∆Cq threshold for this 
QC checkpoint was adopted. Only restored bisulfite con-
verted FFPE tumour-enriched DNA with a ∆Cq value 
of ≥4 was assayed on the HM450K platform.
Infinium HumanMethylation450 Beadchip assay
The Infinium HumanMethylation450 Beadchip assay 
(Illumina, San Diego, CA, USA) was performed as per 
manufacturer’s instructions specific for formalin-fixed 
embedded-material. The following replicates were 
included for every 48 samples to ensure the reproducibil-
ity of data: (1) one technical replicate from good quality 
bisulfite converted cell line DNA (U266 multiple mye-
loma cell line) to test for possible batch effects between 
different reagents and beadchips used, and different 
processing times and (2) one technical replicate from 
restored bisulfite converted FFPE tumour-enriched DNA, 
where each replicate was placed on a different beadchip 
to test for possible chip effects between beadchips.
Data analysis
Data from samples assayed on the HM450K platform 
were imported into the R environment (R Programming 
Software version 2.15.1) as previously described [2] and 
processed using the Minfi package version 1.10.1 [11]. 
The following criteria were applied to evaluate the over-
all data quality and performance of individual samples 
across all probes and individual probes within each sam-
ple, respectively: (1) average detection p-value across all 
probes of p ≤ 0.01; (2) individual probe detection p-value 
of p ≤  0.05. Individual FFPE tumour-enriched DNA or 
probes that failed either criterion were removed from 
further analysis. Any sample with more than 1  % failed 
probes from a total of 485,512 probes were also classed 
as “failed” and excluded for the purposes of this analysis.
Analysis of TCGA HM450K methylation data
Subtype information and associated level 3 methylation 
signals (calculated beta values mapped to the genome) 
from 156 breast tumours were obtained from the TCGA 
Download Portal (https://tcga-data.nci.nih.gov/tcga/
tcgaHome2.jsp) [12]. The data consisted of the following 
subtypes based on the expression of 50 genes and clas-
sified using the prediction analysis of microarray (PAM): 
86 Luminal A, 39 Luminal B, 22 basal-like and 9 HER2-
enriched [13]. The mean beta value, standard deviation 
and 95  % confidence interval (CI) were calculated for 
each of the 48 methylation probes specific to the BRCA1 
gene (5 additional probes were classified as ‘NA’ due to 
having detection p-values  >0.05) across all tumours of 
the same subtype, resulting in 3 values per methylation 
probe for each subtype.
Results
DNA was macrodissected from marked up areas of 474 
FFPE breast tumours. Five samples did not have a detect-
able amount of DNA at QC checkpoint 1. Of the remain-
ing 469 FFPE tumour-enriched DNA samples that were 
progressed past QC checkpoint 2, 42 (8.93  %) samples 
failed to progress past QC checkpoint 3 with ∆Cq values 
ranging from 0 (no amplification) to 3.77. The methylome 
of 427 FFPE tumour-enriched DNA were subsequently 
evaluated on the HM450K platform (Fig. 1). Of these, 4 
(<1 %) had an average detection p-value across all probes 
of ≥0.01 and were removed from further analysis. Based 
on our criteria, 5  % (24,816) of probes were removed, 
with 460,696 common probes remaining across 423 FFPE 
tumour-enriched DNA for downstream data analysis. 
The average detection p-value across these probes for all 
remaining samples (n =  423) was 4.54 ×  10−4 (Fig.  2a) 
with high correlations observed between sample repli-
cates (correlation coefficients r  >  0.98) (Fig.  2b) thereby 
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confirming the capacity of our protocol to generate 
reproducible, high quality data.
We further evaluated the 4 failed samples on the 
HM450K platform and 16 randomly selected ‘success-
ful’ samples at the QC checkpoints (Table 1). We did not 
observe a correlation between age of tumour material 
(8–20 years), performance at any of the QC checkpoints 
and subsequent performance on the HM450K platform.
Performance of internal control probes
We assessed the performance of sample-specific and 
sample-independent internal control probes present 
on the HM450K beadchip (http://www.illumina.com) 
between ‘failed’ and ‘successful’ tumour-enriched DNA 
samples and two unrestored U266 cell line genomic DNA 
(Additional file 1: Figure S1, Additional file 2: Figure S2). 
The performance of the controls probes was variable 
Fig. 2 Post HM450K assay data quality checks of FFPE tumour-enriched DNA. a Average probe detection p-values across all probes for each 
sample. Each black dot represents a single sample. The average detection p–value across all probes for all samples (n = 423) was 4.54 × 10−4. b 
Scatterplots of replicates assayed on different beadchips (n = 11). The average correlation coefficient (rave) across all replicates was 0.993
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between tumour-enriched samples. The majority of the 
control probes for samples 2657 and 3282 which had 
the largest number of failed HM450K probes performed 
poorly and had the highest level of background signal 
amongst the 22 samples evaluated.
Methylation at the BRCA1 gene
The HM450K assay measures methylation at 53 CpG 
sites (53 methylation probes) across the BRCA1 gene. 
Three probes (cg19088651, cg11126247 and cg16919093) 
did not meet the QC criteria and were removed from 
the analysis. The 423 remaining FFPE tumour-enriched 
breast DNA in our study consisted of the following sub-
types: 238 Luminal A, 87 Luminal B, 63 triple-negative 
and 30 HER2-positive. The mean beta value, standard 
deviation and 95  % CI for each BRCA1-specific probe 
across each subtype were calculated and plotted as a line 
graph. Approximately 20 probes along the BRCA1 pro-
moter region displayed higher mean beta levels in the tri-
ple-negative breast tumours compared to other subtypes 
(student’s t-test, p < 10−5) (Fig. 3a). This probe set over-
lapped BRCA1 exon 1, exon 1 of its’ neighbouring gene, 
NBR2 [14] and their shared bi-directional promoter [15].
We sought to compare our results against publicly 
available data from The Cancer Genome Atlas where 
genome-wide methylation was measured using the same 
platform and on DNA extracted from fresh frozen mate-
rial thereby representing good quality DNA [12]. We 
compared methylation signals at BRCA1 between the 
basal-like, Luminal A, Luminal B and HER2-enriched 
breast tumour subtypes and although not at a signifi-
cant level, we observed a similar trend along the same 20 
probes where increased methylation was observed specif-
ically in basal-like breast tumours compared with other 
subtypes (Fig.  3b). An additional two probes within the 
same region of BRCA1 which failed in our dataset also 
displayed the same trend.
Discussion
This protocol facilitated the successful application of the 
HM450K platform to DNA extracted from FFPE tumour 
material and is relevant for any large population-based 
translational epigenetic studies of human disease. This 
assertion is based on assessment of the quality metrics 
and consistency of the data with prior research data 
examining methylation at the BRCA1 promoter.
Methylation of the BRCA1 promoter along with the 
corresponding loss of BRCA1 expression in muta-
tion-negative breast cancer is well described for both 
familial and sporadic breast cancer and has been dem-
onstrated using low-throughput loci-specific methods 
[16–18]. Promoter methylation of this gene has also been 
Table 1 Age of  tumour material, performance at  QC checkpoints and  number of  failed HM450K probes in  failed and  a 
subset of successful samples on HM450K platform
a Denotes failed samples on the HM450K assay (according to study criteria)
Sample Age of tumour material (years) QC 1 (total ng) QC 2 (∆Cq ≤ 6) QC 3 (∆Cq ≥ 4) Number of failed probes
2657a 20 209 1.43 5.45 125,491
3282a 20 483 0.68 8.09 196,914
25098a 11 334 3.25 5.94 28,751
27042a 7 671 1.83 9.84 22,334
1537 15 47 0.86 5.56 502
2245 12 256 1.04 8.16 272
6075 19 27.3 1.00 4.28 788
6112 20 159.8 1.61 6.72 534
8613 18 51.5 1.87 4.64 794
10350 13 1078 2.7 4.83 9995
10780 14 749 4.1 4.24 6678
15291 14 114.6 1.24 6.96 485
17940 17 583 4.13 4.83 5436
21200 10 71.2 1.17 4.17 694
21635 13 172.4 2.73 4.62 1083
35915 9 305 2.78 7.28 512
35995 8 270 4.28 4.00 3379
37246 12 180.5 3.74 4.14 2714
40593 12 63.9 1.64 6.04 1079
41223 11 1579 2.95 6.42 1489
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Fig. 3 Probe mean beta values at the BRCA1 gene. a Mean beta values measured from 419 tumour-enriched DNA in our dataset. Twenty probes 
overlapping exon 1 of BRCA1, exon 1 of NBR2 and their shared bi-directional promoter showed increased methylation in triple-negative breast 
cancers (TNBC) compared with Luminal A (Lum A), Luminal B (Lum B) and HER2-positive (HER2-pos) subtypes (* denotes probes not present in the 
TCGA dataset). b Mean beta values measured from 156 tumour-enriched DNA in TCGA. Twenty-two probes overlapping exon 1 of BRCA1, exon 1 of 
NBR2 and their shared bi-directional promoter showed increased methylation in basal-like breast cancers (TNBC) compared with Luminal A (Lum A), 
Luminal B (Lum B) and HER2-enriched (HER2-pos) subtypes (+ denotes probes not present in our dataset)
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associated with the triple-negative breast cancer subtype 
and/or histological features commonly associated with 
triple-negative breast cancers [19–22].
In our data 20 probes along the BRCA1 promoter 
region displayed higher mean beta levels in the triple-
negative breast tumours compared to other subtypes. 
This region encompassed a region of the BRCA1 pro-
moter (CpG sites −44 to +55 relative to the transcrip-
tion start site and corresponding to the region between 
probes cg19531713 and cg17301289) that has been spe-
cifically measured by MethyLight Real-time PCR in pre-
vious studies [20].
The modified protocol described here incorporates an 
important third QC checkpoint. Assuming all samples 
that failed the QC would have also failed the HM450K 
assay, incorporation of this checkpoint increased the suc-
cess rate of our samples on the HM450K platform from 
90  % to the reported 99  %. Using this modified proto-
col, we were able to identify and remove samples that 
were likely to fail prior to application on the HM450K 
platform.
However, there are several aspects to this data that are 
important to consider further. Firstly, as we excluded 
samples that fell below the described threshold (∆Cq 
value ≥ 4) we do not have data that confirms that these 
samples would not have generated data, on the HM450K 
platform, that met our criterion for success (average 
detection p-value across all probes of p ≤ 0.01 and indi-
vidual probe detection p-value of p  ≤  0.05). The costs 
associated with running this platform makes this chal-
lenging to test, but data from 2 archival FFPE tumour 
samples which failed QC checkpoint 3 (∆Cq 2.52 and 0) 
in a subsequent study in our laboratory produced very 
poor quality data with 61,803 and 200,552 failed probes, 
respectively [data not shown]. This finding supports our 
protocol to exclude samples with ∆Cq value  ≤4 at QC 
checkpoint 3.
Secondly, the BRCA1 promoter amplicon utilised in 
QC checkpoint 3 includes CpGs sites. Although our 
methodology was developed to balance amplification 
of both the methylated and non-methylated template 
[10], this is difficult to achieve due to potential PCR bias 
favouring the amplification of the unmethylated template 
[23]. Our assay was not designed to differentiate between 
methylated and unmethylated template but, if this is 
important to other related applications, it would be more 
appropriate to select an alternate amplicon (without CpG 
sites) that would offer a superior assay.
We are also aware that we cannot exclude the possi-
bility of Loss of Heterozygosity or homozygous deletion 
at the BRCA1 locus being responsible for a proportion 
of the QC checkpoint failures. Further investigation 
using other molecular techniques such as Multiplex 
Ligation-dependent Probe Analysis (MLPA) and Sanger 
sequencing of heterozygous SNPs flanking this region is 
certainly warranted but not within the scope of this tech-
nical report.
The performance of the HM450K internal control 
probes did not always correlate with the detection 
p-values. For instance, the internal control probes for 
sample 27042 performed satisfactorily although hav-
ing a high number of probes with detection p-val-
ues  >0.05. In contrast, sample 35995 passed all our 
data QC hurdles although some of the bisulfite conver-
sion II control probes showed higher background sig-
nal intensities.
This protocol is suitable for the analysis of macrodis-
sected FFPE tumour-enriched DNA samples of variable 
quantities and quality and can be reliably and systemati-
cally applied to hundreds of samples in a standard and 
controlled manner. Moreover, it has the potential to be 
translated into molecular pathology diagnostic services 
as the assessment of methylation becomes more clini-
cally applied in the diagnosis and treatment of disease. 
This methodology will have utility in population-based 
translational epigenetic studies and is applicable to a 
wide variety of translated studies interested in analysis of 
methylation and its role in the predisposition to disease 
and disease progression.
Conclusions
This protocol facilitated the successful application of the 
HM450K platform to DNA extracted from archival FFPE 
tumour material and is relevant any large population-
based translational epigenetic studies of human disease.
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Additional file 1: Figure S1. Performance of HM450K sample-inde-
pendent control probes for failed and a subset of successful samples. 
Sample-independent control probes measured the staining (A), extension 
(B), target removal (C) and hybridisation (D) steps in the HM450K assay on 
the red and green channels. Failed samples are boxed.
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